Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia

BACKGROUND: Benign prostatic hyperplasia (BPH) refers to non‐malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha‐blockers (ABs) and 5‐alpha reductase inhibitors (5‐ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cochrane Database Syst Rev
Hlavní autoři: Pattanaik, Smita, Mavuduru, Ravimohan S, Panda, Arabind, Mathew, Joseph L, Agarwal, Mayank M, Hwang, Eu Chang, Lyon, Jennifer A, Singh, Shrawan K, Mandal, Arup K
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Ltd 2018
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517182/
https://ncbi.nlm.nih.gov/pubmed/30480763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010060.pub2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky